微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
STAT+: FDA approves Roivant therapy for rare autoimmune disease
RSS 官方收录 · 可信分层展示
关键摘要
The Food and Drug Administration on Thursday approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune disease characterized by muscle weakness and a painful skin rash.…
- The drug, called brepocitinib, will be marketed under the brand name L…
- It’s a pill taken once daily.
- High doses of steroids and other immune-suppressing drugs are the curr…
摘要引擎：抽取
正文提要
The Food and Drug Administration on Thursday approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune disease characterized by muscle weakness and a painful skin rash.
The drug, called brepocitinib, will be marketed under the brand name Lisraya. It’s a pill taken once daily.
High doses of steroids and other immune-suppressing drugs are the current standard of care for patients with dermatomyositis, which affects between 40,000 and 70,000 people in the U.S., according to Roivant.